S98
Brachytherapy - Head & neck, skin, eye
ESTRO 2026
EBRT-dose to the tumor site was 55.8 Gy (IQR: 50.4–56 Gy), the median neck dose ranged from 50 to 66 Gy. Thirty-three patients (60%) received concomitant chemotherapy.Interstitial HDR-IRT delivered twice daily to the tumor-volume with a 10–15 mm safety margin with a median 12 Gy dose (IQR: 10–15 Gy). The HDR-IRT boost was prior to EBRT in 23 patients (41.8%) and after EBRT in 32 patients (58.2%).
systems with proper organisation and training, ensuring patients with ocular tumours have access to high-quality, conservative management. Keywords: uveal melanoma, multidisciplinary References: Marinkovic M, Horeweg N, Laman MS, et al. Ruthenium-106 brachytherapy for iris and iridociliary melanomas. British Journal of Ophthalmology 2018;102:1154-1159.American Brachytherapy Society - Ophthalmic Oncology Task Force. The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma. Brachytherapy. 2014 Jan-Feb;13(1):1- 14.Collaborative Ocular Melanoma Study Group. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report No. 28. Arch Ophthalmol. 2006 Dec;124(12):1684-93. Interventional Radiotherapy (Brachytherapy) Boost with External Radiation for Base of Tongue Squamous Cell Carcinoma (BOTSCC) Tamer Soror 1 , Pierre-Alexander Justenhoven 1 , Warren Bacorro 2 , György Kovács 3 , Dirk Rades 1 , Karl-Ludwig Bruchhage 4 , Anke Leichtle 4 1 Radiation Oncology Department,, University of Lübeck/UKSH-CL, Lübeck, Germany. 2 Department of Radiation Oncology,, Benavides Cancer Institute, University of Santo Tomas Hospital, Manila, Philippines. 3 Gemelli-INTERACTS, Università Cattolica del Sacro Cuore, Rome, Italy. 4 Department of Oto- Rhino-Laryngology and Head and Neck Surgery, University of Lübeck, Lübeck, Germany Purpose/Objective: To evaluate the efficacy and safety of high-dose-rate interventional radiotherapy (brachytherapy, HDR-IRT) boost with external-beam-radiation treatment (EBRT) in the adjuvant treatment of advanced non-metastatic BOTSC after organ-preserving surgery. Material/Methods: Digital Poster Highlight 1104 We reviewed 55 newly diagnosed BOTSCC cases treated with HDR-IRT+EBRT between 2008-2022. The median age was 59 years, with 2.24 male-to-female ratio. Surgical treatment included local excision (14, 25.5%) and wide excision (41, 74.5%), with ipsilateral (50.1%) or bilateral (49.9%) neck-dissection. Resection margins were negative in 14 patients (25.5%), close (<5 mm) in 32 (58.2%), microscopically-positive in 2 (3.6%), and macroscopically-positive in 7 (12.7%).The median
Results:
The median follow-up was 46 months. The 5-year local failure-free survival rate was 85%, regional failure-free survival 96%, metastasis-free survival 86%, and overall survival 90%. No subsequent glossectomy, yielding a
Made with FlippingBook - Share PDF online